Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 7;11:1. doi: 10.1038/s41598-020-79139-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Longitudinal analysis of Hsp90 plasma levels in patients with SSc-ILD treated with cyclophosphamide. (a) No significant differences in plasma Hsp90 were detected between baseline and after 1, 6, and 12 months of therapy with cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The red line represents the median. Friedman's test was used for all comparisons. (b) Lower baseline levels of plasma Hsp90 were significantly associated with larger improvement in diffusing lung capacity for carbon monoxide at month 12 from baseline (ΔDLCO% predicted) upon cyclophosphamide treatment. (c) Differences in plasma Hsp90 levels at baseline and one month thereafter in patients grouped according to the course of pulmonary function during the observation time, classified by deterioration and stabilization or improvement of DLCO% predicted at month 12 with respect to baseline. Descriptions of deterioration, stabilization, and improvement are stated in the text. Values are presented as box plots: the boxes represent the 25th–75th percentiles, the lines within the boxes represent the median, and the whiskers represent minimum to maximum.